Carnegie acted as joint global co-cordinator in the directed new share issue of 3,660,000 new shares at a subscription price of SEK 82 per share. Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. December 2019.
Healthcare
Directed new share issue in Camurus AB (SE) — SEK 300 million
December 2019